ArticleJournal of hematology & oncology2022

Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation.

Toshio Fujino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.